Compare UBER & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UBER | GKOS |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | 36600 | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.8B | 10.6B |
| IPO Year | 2019 | 2015 |
| Metric | UBER | GKOS |
|---|---|---|
| Price | $69.28 | $154.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 33 | 12 |
| Target Price | $107.03 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 15.8M | 601.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.73 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $52,017,000,000.00 | $507,442,000.00 |
| Revenue This Year | $14.41 | $23.32 |
| Revenue Next Year | $14.29 | $27.43 |
| P/E Ratio | $54.26 | ★ N/A |
| Revenue Growth | 18.28 | ★ 32.33 |
| 52 Week Low | $65.41 | $73.16 |
| 52 Week High | $101.30 | $191.62 |
| Indicator | UBER | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | N/A |
| Support Level | $69.28 | N/A |
| Resistance Level | $78.21 | N/A |
| Average True Range (ATR) | 1.85 | 0.00 |
| MACD | -0.49 | 0.00 |
| Stochastic Oscillator | 4.06 | 0.00 |
Uber is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars and autonomous vehicles, but could eventually support additional products and services, such as drone delivery or electric vertical takeoff and landing (eVTOL) technology. Uber operates in over 70 countries and has over 200 million users who order rides or food at least once a month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.